<scp>SCI</scp> : A Bayesian adaptive phase I/ <scp>II</scp> dose‐finding design accounting for <scp>semi‐competing</scp> risks outcomes for immunotherapy trials-Reference-Cited by-同舟云学术

SCI : A Bayesian adaptive phase I/ II dose‐finding design accounting for semi‐competing risks outcomes for immunotherapy trials

Author:

Zhang Yifei¹²,Guo Beibei³^ORCID,Cao Sha²⁴,Zhang Chi⁴⁵,Zang Yong²⁴^ORCID

Affiliation:

1. Department of Statistics and Programming Jiangsu Hengrui Pharmaceuticals Co. Ltd. Shanghai China

2. Department of Biostatistics and Health Data Science Indiana University Indianapolis Indiana USA

3. Department of Experimental Statistics Louisiana State University Baton Rouge Louisiana USA

4. Center of Computational Biology and Bioinformatics Indiana University Indianapolis Indiana USA

5. Department of Medical and Molecular Genetics Indiana University Indianapolis Indiana USA

Funder

National Science Foundation of Sri Lanka

Indiana University

Louisiana Board of Regents

National Institutes of Health

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology,Statistics and Probability

Link

Reference32 articles.

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献